Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
Pharmacology, Toxicology and Pharmaceutical Science
7
5%
Nursing and Health Professions
5
3%
Other
15
10%
Unknown
33
22%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2021.
All research outputs
#3,470,319
of 31,520,336 outputs
Outputs from Journal of Clinical Oncology
#9,018
of 29,159 outputs
Outputs of similar age
#11,565
of 133,010 outputs
Outputs of similar age from Journal of Clinical Oncology
#59
of 332 outputs
Altmetric has tracked 31,520,336 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 29,159 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 133,010 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 332 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.
